AIM
SLS icon

Acrospire Investment Management’s SELLAS Life Sciences SLS Stock Holding History

Acrospire Investment Management’s Portfolio SLS Stock Details SLS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2017
Q1 		– Sell
-9
Closed -$25K – 2466
2016
Q4 		$25K Buy
+9
New +$52.3K 0.01% 1695

Other funds holding SLS

SM
Sabby Management Miami Beach, Florida $111M AUM 74.4% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Millennium Management
Millennium Management New York $276B AUM 44.8% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $875B AUM 40.91% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $860B AUM 41.15% 1-Year Est. Return
SG Americas Securities
SG Americas Securities New York $179B AUM 65.34% 1-Year Est. Return

Acrospire Investment Management's SLS Position: Q1 2017 in Review

Acrospire Investment Management sold out of SELLAS Life Sciences (SLS) in Q1 2017, closing a stake of 9 shares — an estimated $25K sold.

Acrospire Investment Management first reported a position in SLS in Q4 2016 and held it in 1 quarter. The position peaked at $25K in Q4 2016. 50 funds tracked by Wall St. Rank hold SLS as of Q1 2017.

  • Acrospire Investment Management reported no remaining SELLAS Life Sciences position as of Q1 2017 after selling out during the quarter.
  • Acrospire Investment Management sold 9 SELLAS Life Sciences shares in Q1 2017, an estimated $25K.
  • Acrospire Investment Management first reported a position in SELLAS Life Sciences in Q4 2016 and held it in 1 quarter.
  • Acrospire Investment Management's SELLAS Life Sciences position peaked at $25K in Q4 2016.
  • 50 funds tracked by Wall St. Rank held SELLAS Life Sciences as of Q1 2017.

Based on Acrospire Investment Management's 13F filing for Q1 2017, filed 4 May 2017.